In a not-so-surprising move, Sanofi finally ended its distribution agreement with MannKind for the inhaled insulin Afrezza -- a move that could mean a slow death for the biotech, despite its claims to the contrary.
The French pharma's move to return rights to the drug should come as no shock to investors or anyone who...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?